FGFR2 (C491F)

FGFR2 · Variant type: point · HGVS: p.C491F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ibrutinib	100.0%	0.0%	94.74
2	Lapatinib	100.0%	0.0%	99.25
3	Dacomitinib	100.0%	0.0%	97.99
4	Infigratinib	99.0%	1.0%	98.24
5	Erdafitinib	98.6%	1.4%	95.71
6	Pemigatinib	98.6%	1.4%	98.23
7	Brigatinib	97.0%	3.0%	82.96
8	Selpercatinib	94.5%	5.5%	96.72
9	Pazopanib	92.8%	7.2%	97.49
10	Ripretinib	91.2%	8.8%	92.95
11	Vandetanib	89.7%	10.3%	95.74
12	Deucravacitinib	88.9%	11.1%	98.99
13	Entrectinib	83.8%	16.1%	93.69
14	Repotrectinib	81.3%	18.7%	84.21
15	Sunitinib	73.5%	26.5%	91.73
16	Pralsetinib	72.2%	27.8%	93.43
17	Tivozanib	71.3%	28.7%	92.42
18	Defactinib	62.5%	37.5%	92.68
19	Fostamatinib	59.4%	40.6%	96.74
20	Canertinib	53.4%	46.6%	96.49
21	Tepotinib	53.3%	46.7%	99.75
22	Futibatinib	53.2%	46.8%	98.48
23	Sorafenib	51.1%	48.9%	96.72
24	Fedratinib	47.3%	52.7%	96.21
25	Pacritinib	46.1%	53.9%	88.64

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ibrutinib	100.0%	—	—
Lapatinib	100.0%	—	—
Dacomitinib	100.0%	—	—
Infigratinib	99.0%	98.8%	+0.2%
Erdafitinib	98.6%	99.0%	-0.4%
Pemigatinib	98.6%	98.7%	-0.1%
Brigatinib	97.0%	96.1%	+0.9%
Selpercatinib	94.5%	95.0%	-0.5%
Pazopanib	92.8%	88.9%	+3.9%
Ripretinib	91.2%	85.4%	+5.9%
Vandetanib	89.7%	90.8%	-1.2%
Deucravacitinib	88.9%	92.5%	-3.6%
Entrectinib	83.8%	81.5%	+2.3%
Repotrectinib	81.3%	79.8%	+1.5%
Sunitinib	73.5%	—	—
Pralsetinib	72.2%	93.2%	-21.0%
Tivozanib	71.3%	—	—
Defactinib	62.5%	—	—
Fostamatinib	59.4%	—	—
Canertinib	53.4%	—	—
Tepotinib	53.3%	—	—
Futibatinib	53.2%	99.3%	-46.1%
Sorafenib	51.1%	—	—
Fedratinib	47.3%	—	—
Pacritinib	46.1%	—	—

Cancer	Organ	Source
endometrial_carcinoma	Uterus	ref
carcinoma_liver	Liver	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 21.7ms